The Avastin Crisis: A Crisis in Patient Blindness

The Avastin Crisis: A Crisis in Patient Blindness

Biswas, S.; Gedjeyan, M.; and O’Rourke, J.S. (Editor) Notre Dame
February 12, 2018
SKU: BUS-314

Region of the world: North America
Topic: Strategy & General Management
Price: $4.00 | €0.00
No votes yet

In spite of similar formulation, Swiss pharmaceuticals giant Roche has always positioned its two products Avastin and Lucentis separately, as treatments for cancer and for age-related macular degeneration (AMD) respectively. However, doctors have been prescribing Avastin for AMD treatments because of the huge price differential between the two drugs. With contamination of Avastin due to repackaging by a Florida pharmacy leading to 21 cases of patient blindness in Q3 2011, Roche faces a serious threat to its reputation and finances. 11 pp. Case #11-09 (2011)